Insulet Corporation (NASDAQ:PODD) Given Average Rating of “Moderate Buy” by Analysts

Insulet Corporation (NASDAQ:PODD) has earned an average rating of “Moderate Buy” from the twenty-four analysts that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and twenty have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $374.0952.

PODD has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Stifel Nicolaus cut their target price on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Leerink Partners increased their price target on Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Royal Bank Of Canada lifted their price objective on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Raymond James Financial increased their target price on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 21st.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC grew its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. Elyxium Wealth LLC purchased a new position in Insulet during the fourth quarter valued at $28,000. True Wealth Design LLC lifted its position in Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 72 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares during the period. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA increased its position in Insulet by 68.8% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 55 shares in the last quarter.

Insulet Trading Up 0.8%

PODD opened at $242.74 on Tuesday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. Insulet has a 52 week low of $230.05 and a 52 week high of $354.88. The stock has a market cap of $17.08 billion, a PE ratio of 70.36, a PEG ratio of 1.37 and a beta of 1.41. The business has a 50 day moving average of $276.12 and a 200-day moving average of $306.11.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.